The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Researchers Seek to Predict & Prevent Rheumatoid Arthritis

Researchers Seek to Predict & Prevent Rheumatoid Arthritis

June 21, 2018 • By Jeffrey A. Sparks, MD, MMSc, & Kevin D. Deane, MD, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Notably, factors related to the strength of a prediction estimate, and type, safety and length of therapy, apply to what an individual may be willing to do for prevention, as well as what investigators and ethical reviewers may be willing to give to an individual. For example, if a predictive model suggests an individual is at ~10% risk for the development of clinically apparent RA within the next 10 years, that individual and investigators/ethical boards may wish only to do lifestyle interventions or very safe drug therapy. Conversely, if a predictive model suggests that an individual has ~80% risk for developing clinically apparent RA within two years, an individual and investigators/ethical boards may be more willing to participate in a drug study with a therapy that may have some risk for adverse effects.

You Might Also Like
  • Researchers Work Toward Early ID & Treatment of Rheumatoid Arthritis
  • 2013 ACR/ARHP Annual Meeting: Researchers Explore Role of Pathogens, Quality of Care in Rheumatoid Arthritis
  • Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium
Explore This Issue
June 2018

The field will also need to have clear nomenclature to define stages/phases of disease that may benefit from intervention, but perhaps do not yet meet more established classification criteria (e.g., 2010 ACR/EULAR RA Classification criteria). For example, pre-diabetes is a well understood and widely used term used to define a risk period during which interventions may reduce the risk for developing the worse disease of diabetes.28 Efforts to develop terminology that can be applied across the development of RA are not yet widely implemented and may need additional work once the natural history of preclinical RA, and the point at which lifestyle and pharmacologic interventions are best to intervene, are determined.29

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The optimal metrics for judging success of an intervention, including measuring when an intervention could be tapered or possibly stopped, are also future aims for research, particularly in the prevention setting, when patients may not have symptoms. Patient-reported outcomes (including digital health), joint examinations and imaging (e.g., ultrasound) may help demonstrate that an individual has not transitioned to classifiable disease. However, blood-based biomarkers may also be highly important to follow to watch inflammation or degrees of autoimmunity—much like cholesterol levels are followed to determine if lifestyle or drug therapy is successful. For RA, such biomarkers could be inflammatory markers or autoantibodies. Although ACPA and RF are not typically followed in individuals who have developed classifiable RA, perhaps in prevention a reduction in autoantibody level or even a reversion to levels below the cutoff value for a positive test may be strong indicators of success. In addition, as advanced imaging, such as ultrasound and magnetic resonance imaging, becomes increasingly available, these modalities may need to be considered in follow-up.

Pages: 1 2 3 4 5 6 7 8 | Single Page

Filed Under: Rheumatoid Arthritis Tagged With: lifestyle, Metrics, risk assessment, Risk FactorsIssue: June 2018

You Might Also Like:
  • Researchers Work Toward Early ID & Treatment of Rheumatoid Arthritis
  • 2013 ACR/ARHP Annual Meeting: Researchers Explore Role of Pathogens, Quality of Care in Rheumatoid Arthritis
  • Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium
  • 2013 ACR/ARHP Annual Meeting: Genetic Research Yields Clues to Pathogenesis of Rheumatoid Arthritis, Psoriatic Arthritis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)